Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds Sustainability Profile
Eli Lilly and Company, commonly known as Eli Lilly, is a prominent global pharmaceutical firm headquartered in the United States. Founded in 1876, the company has established itself as a leader in the biopharmaceutical industry, focusing on innovative treatments across various therapeutic areas, including oncology, diabetes, and immunology. With a strong presence in North America, Europe, and Asia, Eli Lilly is renowned for its commitment to research and development, particularly in novel pre-clinical compounds. The company’s core products, such as insulin and cancer therapies, are distinguished by their efficacy and patient-centric approach. Eli Lilly's notable achievements include pioneering advancements in diabetes care and maintaining a robust pipeline of potential therapies, solidifying its position as a key player in the global healthcare landscape.
DitchCarbon Score
How does Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds's score of 50 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds, currently does not have specific carbon emissions data available for the most recent year. The organisation is part of a corporate family that cascades emissions data from Thermo Fisher Scientific Inc., which is at cascade level 6. However, no specific emissions figures or reduction targets have been provided. In terms of climate commitments, Eli Lilly & Co. has not outlined any specific reduction initiatives or targets, such as those set by the Science Based Targets initiative (SBTi). The absence of documented reduction targets suggests that the company may still be in the early stages of formalising its climate strategy. As a merged entity, Eli Lilly & Co. may benefit from the climate initiatives and commitments of its parent organisation, Thermo Fisher Scientific Inc. However, without explicit data or targets, it is challenging to assess the company's current carbon footprint or its long-term climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 321,190,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 486,151,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds's Industry?
How Carbon Intensive is Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds's Location?
Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds's Scope 3 Categories Breakdown
Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds's Scope 3 emissions, which decreased by 26% last year and decreased by approximately 37% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 58% of Scope 3 emissions.
Top Scope 3 Categories
Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
